- Expert consensus on the practical aspects of collaboration between cardiologists and diabetologists in the management of patients with chronic heart failure with reduced ejection fraction2021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction +12021 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial2022 | Publication without faculty affiliation
- Assessment of left ventricular diastolic function by radionuclide ventriculography in patients with chronic heart failure and reduced ejection fraction2014 | Central Library of Charles University, Third Faculty of Medicine
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction2019 | First Faculty of Medicine
- Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index2021 | First Faculty of Medicine
- Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF2020 | First Faculty of Medicine
- The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction2021 | First Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF2021 | First Faculty of Medicine
- Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction2021 | First Faculty of Medicine
- Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. A Post Hoc Analysis of the DAPA-HF Trial2022 | First Faculty of Medicine
- Statistical analysis plan for a randomized controlled trial examining pedometer-based walking intervention in patients with heart failure with reduced ejection fraction: the WATCHFUL trial2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Akutní pokles odhadované glomerulární filtrace po enalaprilu a mortalita a kardiovaskulární výsledné ukazatele u pacientů se srdečním selháním se sníženou ejekční frakcí2019 | First Faculty of Medicine
- Quality of life and sacubitril/valsartan2019 | First Faculty of Medicine
- Chronic heart failure2015 | First Faculty of Medicine
- Chronic heart failure, part 1. Terminology, epidemiology and diagnosis2015 | First Faculty of Medicine
- Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure2023 | First Faculty of Medicine
- What's new in the diagnosis and treatment of heart failure2016 | First Faculty of Medicine
- Comment on ESC/CSC Guidelines Diagnosis of heart failure2016 | First Faculty of Medicine
- News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction2023 | First Faculty of Medicine
- Controversies accumulated around betablockers2015 | First Faculty of Medicine
- Bimodal distribution of QRS complex duration in patients with dilated cardiomyopathy undergoing an ICD implant procedurePublication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BAY 15371Publication without faculty affiliation
- Gliflozins and heart failure - what is and will be new?2021 | First Faculty of Medicine
- Oversights and mistakes in heart failure therapy with left ventricular dysfunction2018 | First Faculty of Medicine
- Sacubitril/valsartan - new dual inhibitor of neprilysin and angiotensin II receptors2016 | First Faculty of Medicine
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure2021 | First Faculty of Medicine
- Sacubitril/valsartan in the treatment of chronic heart failure2016 | First Faculty of Medicine
- Pharmacological therapy for chronic heart failure2018 | First Faculty of Medicine